Ratings Welcia Holdings Co., Ltd.

Equities

3141

JP3274280001

Market Closed - Japan Exchange Other stock markets 07:00:00 28/06/2024 BST			5-day change	1st Jan Change
2,006 ^JPY	-0.40%		+0.83%	-18.65%

04-22	Inageya to Book Extraordinary Income of 1.62 Billion Yen in Fiscal 2025 After Share Transfer Agreement with Aeon and Welcia	MT
04-17	Japan's Welcia says president steps down due to 'inappropriate behaviour'	RE

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.35 for the 2025 fiscal year.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
WELCIA HOLDINGS CO., LTD.	-18.65%	2.58B		C-
WALGREENS BOOTS ALLIANCE, INC.	-53.68%	10.44B		B-
JD HEALTH INTERNATIONAL INC.	-45.65%	8.68B		B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-26.18%	6.45B		B
MATSUKIYOCOCOKARA & CO.	-7.49%	5.98B		C+
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+85.61%	4.91B		C
NAHDI MEDICAL COMPANY	-3.80%	4.57B		D-
CLICKS GROUP LIMITED	+5.73%	4.49B		B
YIFENG PHARMACY CHAIN CO., LTD.	-26.42%	4.1B		C
SAUDI CHEMICAL HOLDING COMPANY	+161.11%	2.54B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes